Chemotherapy
Perioperative discordance in mesothelioma cell type after pleurectomy/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?
Interdisciplinary Cardiovascular Thoracic Surgery 2023 November 2 [Link] Luigi Ventura, Michelle Lee, Ralitsa Baranowski, Joanne Hargrave, Michael Sheaff, David Waller Abstract Objectives: The goal was to evaluate the accuracy of preoperative histological assessment and the factors affecting the accuracy and the subsequent effect on postoperative survival after surgical treatment for malignant pleural mesothelioma (MPM). Methods:…
Read MoreTargeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo
Cancer Letters 2023 October 10 [Link] Karin Schelch, Dominik Emminger, Benjamin Zitta, Thomas G Johnson, Verena Kopatz, Sebastian Eder, Alexander Ries, Alessia Stefanelli, Petra Heffeter, Mir A Hoda, Konrad Hoetzenecker, Balazs Dome, Walter Berger, Glen Reid, Michael Grusch Abstract Pleural mesothelioma (PM) is characterized by poor prognosis and limited therapeutic options. Y-box-binding protein 1 (YB-1)…
Read MoreKrebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma
Lung Cancer 2023 September 7 [Link] Paul Stockhammer, Hannah Baumeister, Till Ploenes, Francesco Bonella, Dirk Theegarten, Balazs Dome, Christine Pirker, Walter Berger, Luca Hegedüs, Marcell Baranyi, Martin Schuler, Sophie Deshayes, Servet Bölükbas, Clemens Aigner, Christophe Blanquart, Balazs Hegedüs Abstract Objectives: Pleural mesothelioma (PM) is a rare disease with dismal outcome. Systemic treatment options include chemotherapy…
Read MoreHigh-dose IV magnesium in mesothelioma patients receiving surgery with hyperthermic intraoperative cisplatin: Pilot studies and design of a phase II randomized clinical trial
Journal of Surgical Oncology 2023 September 13 [Link] Shruti Gupta, Sophia L Wells, Arunima M Jose, Robert H Seitter, Lea Feghali, Nishant Devaraj, Philip M Hartigan, Stephanie Yacoubian, David J Kwiatkowski, Donna M Burke, Julianne Barlow, Raphael Bueno, David E Leaf Abstract Introduction: Hyperthermic intraoperative cisplatin (HIOC) is associated with acute kidney injury (AKI). Administration…
Read MoreInduction of metallothionein expression by supplementation of zinc induces resistance against platinum-based treatment in malignant pleural mesothelioma
Translational Cancer Research 2023 August 31 [Link] Martine Wyrich, Henning Ohlig, Michael Wessolly, Elena Mairinger, Julia Steinborn, Luka Brcic, Balazs Hegedus, Thomas Hager, Kristina Greimelmaier, Jeremias Wohlschlaeger, Fabian D Mairinger, Sabrina Borchert Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal prognosis. Currently, multimodality treatment including chemotherapy with cisplatin or carboplatin…
Read MoreZimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature
World Journal of Clinical Cases 2023 August 6 [Link] Xiao-Dong Peng, Zhen-Yu You, Lian-Xiang He, Qi Deng Abstract Background: Malignant peritoneal mesothelioma (MPeM) is a rare cancer with a poor prognosis at advanced stage, and the standard first-line treatment for inoperable patients is chemotherapy. Although combining programmed cell death 1 (PD-1) inhibitors with chemotherapy is…
Read MoreCost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
Pharmacoeconomics 2023 August 12 [Link] Michaela Carla Barbier, Alicia Fengler, Esther Pardo, Arjun Bhadhuri, Niklaus Meier, Oliver Gautschi Abstract Background: Malignant pleural mesotheliomas (MPMs) are aggressive and often unresectable. In the past, chemotherapy was the standard for palliative treatment. However, immunotherapy with nivolumab+ipilimumab has recently received marketing approval. Objectives: This study evaluated the cost effectiveness…
Read MoreHyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease
Journal of Surgical Oncology 2023 September [Link] Daniel L Miller, Christopher S Parks, Brittany Ange, Ioana R Bonta, Patricia T Rich Abstract Objectives: Pleural metastasis has extremely poor prognosis. Resection of pleural implants with infusion of intrathoracic hyperthermic chemotherapy may offer a survival advantage in selected patients. We evaluated the safety and efficacy of hyperthermic…
Read MoreLongitudinal monitoring of response to chemotherapy in patients with malignant pleural mesothelioma by biomarkers
Cancer Biomarkers 2023 [Link] Filiz Bogar, Guntulu Ak, Selma Metintas, Adnan Ayhanci, Muzaffer Metintas Abstract Background: The aim of the study was to longitudinally investigate the serum levels of mesothelin, sestrin1, hyaluronan synthase 2 (HAS2), midkine, and high mobility group box 1 (HMGB1) before and after chemotherapy and at the time of relapse in malignant…
Read MoreExpression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients
Cancers 2023 July 14 [Link] Susana Cedres, Garazi Serna, Alberto Gonzalez-Medina, Augusto Valdivia, Juan David Assaf-Pastrana, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Ilaria Priano, Roberta Fasani, Xavier Guardia, Javier Gonzalo, Caterina Carbonell, Joan Frigola, Ramon Amat, Victor Navarro, Rodrigo Dienstmann, Ana Vivancos, Paolo Nuciforo, Enriqueta Felip Abstract MPM is an aggressive…
Read More